Memorial Sloan Kettering Cancer Center
The purpose of this study is to find out whether CD371-YSNVZ-IL18 CAR T cells are safe, and to look for the highest dose of CD371-YSNVZ-IL18 CAR T cells that cause few or mild side effects in participants.
Inclusion Criteria: Subject Inclusion: Collection of T cells (Part A) * History of CD371+ AML * Any disease status is eligible for collection * Expression of CD371 at any level on AML blasts (any method of detection including IHC and/or flow cytometry) * Age/Weight * Pediatrics: ≥ 1 year and ≥ 10kg for collection for dose levels, 1, 2, and -1 * ≥ 12 years and ≥ 40 kg for collection for dose level 1A. * Adults: no limit on age/weight for collection for dose levels 1, 2, and -1. * ≥ 40 kg for collection for dose level 1A. * Patients with history of allo-HCT are eligible for colle…
Cohorts will be infused with escalating doses of CD371-specific/YSNVz/IL-18 CAR T cells with lymphodepleting chemotherapy (LDC) to establish the maximum tolerated dose (MTD). There is a third, lower dose level (step-down dose) available for dose de-escalation in the event of severe toxicity at the first planned dose level.